Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 6 | Biological Research

Fig. 6

From: Maraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival

Fig. 6

In vivo assay. A) Schematic subcutaneous tumor formation in BalbC NOD/SCID mice from tumoroids. (B) Tumor volumes of animals treated with MVC and/or CDDP were measured on day 21. (C) Time course of tumor formation in animals treated with MVC and/or CDDP. Mixed-effect analysis followed by Tukey’s multiple comparison test was used (*P ≤ 0.05, **P < 0.01). Data were expressed as mean ± SEM of three biological replicates) D) Survival chart of animals treated with MVC and/or CDDP. The Log-rank (Mantel-Cox) test was used to assess animal survival. The overlap of the survival curves for the control group, the group treated with MVC, and the group treated with the MVC/CDDP combination indicates that there were no deaths before euthanasia, in contrast to the group treated with CDDP alone. Values of P ≤ 0.05 were considered statistically significant. Maraviroc (MVC) and Cisplatin (CDDP)

Back to article page